Tag: stock exchange

All amounts in Canadian dollars unless otherwise stated.

CALGARY, Alberta, June 01, 2026 (GLOBE NEWSWIRE) -- PrairieSky Royalty Ltd. ("PrairieSky" or the "Company") (TSX: PSK) is pleased to announce that the Toronto Stock Exchange (the "TSX") has accepted the notice of PrairieSky's intention to commence a normal course issuer bid (the "NCIB").

Not for distribution to U.S. newswire services nor for dissemination to the United States
All amounts in Canadian dollars

Hong Kong, June 01, 2026 (GLOBE NEWSWIRE) -- JM Group Limited (NYSE American: JMG) (the “Company” or “JMG”), a Hong Kong-headquartered sourcing and wholesale solutions provider for a wide array of consumer products, today provided the following further updates regarding the Company’s response to the trading halt placed by the New York Stock Exchange (“NYSE”) and the relevant regulatory inquiries previously announced by the Company on February 2, 2026.

GUELPH, Ontario, May 29, 2026 (GLOBE NEWSWIRE) -- (TSX: HPS.A) The Board of Directors of Hammond Power Solutions Inc. (“HPS”) declared a quarterly cash dividend of twenty-seven and a half cents ($0.275) per Class A Subordinate Voting Share of HPS and a quarterly cash dividend of twenty-seven and a half cents ($0.275) per Class B Common Share of HPS payable on June 17, 2026, to shareholders of record at the close of business on June 10, 2026. The ex-dividend date is June 10, 2026.

Seasoned international finance leader to support Kyivstar’s continued growth and digital transformation

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Enigmatig Limited (NYSE American: EGG) (“Enigmatig” or the “Company”), a global business enabler empowering small and medium-sized enterprises (SMEs) to scale across borders, today rang the Closing Bell at the New York Stock Exchange (“NYSE”) to mark its recent listing and reaffirm its mission to power the global ambitions of bold, forward-thinking businesses.

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy^® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.

GREENWICH, Conn., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Associated Capital Group, Inc. (NYSE: AC) (“AC” or the “Company”) announced today that it has given formal notice to the New York Stock Exchange (“NYSE”) of its intention to voluntarily delist its Class A common stock (the “common stock”) from the NYSE and to deregister under Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”). Following the de-listing from the NYSE, we expect to provide liquidity to AC’s Class A stock shareholders by listing AC Class A on the OTCQX platform (the “OTCQX”). AC plans on filing a Form 25 with the U.S. Securities and Exchange Commission (the “SEC”) on or about August 25, 2025. The last day of trading in AC’s common stock on the NYSE will be on or about September 4, 2025, when the Form 25 takes effect. Ninety days thereafter, AC’s common stock deregistration is expected to become effective. When AC files Form 15 on or about September 4, 2025, its filing obligations under the Exchange Act will immediately be suspended or terminated, including the filing of all reports on Forms 8-K, 10-Q and 10-K.

CALGARY, Alberta, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Peyto Exploration & Development Corp. (TSX: PEY) ("Peyto") confirms that the monthly dividend with respect to August 2025 of $0.11 per common share is to be paid on September 15, 2025, for shareholders of record on August 31, 2025.